Across TCGA pan-cancer cohorts, MIR4279 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of MIR4279’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR4279 RNA is repressed in tumor relative to normal tissue. In most cancer types MIR4279 is over-expressed in tumor, although a few such as BRCA and KIRC show the opposite, repressed pattern.
BRCA, LUAD, and KIRC are the cancer types where MIR4279 tumor–normal differential expression is most reproducible.